



FOR IMMEDIATE RELEASE

NuSep Board Changes

Sydney, Australia 19th March 2012 - NuSep (ASX: NSP) wishes to advise the market that, following on from the appointment on Wednesday 14th March 2012 of Mr Andrew Goodall to the Board, that Mr William Spee has resigned today from the Board of NuSep.

Mr Spee has been a strong supporter of the Company since joining the Board in September 2009 as both a Board member and a significant shareholder.

These recent Board changes reflect the restructuring of the Board in anticipation of NuSep's establishment of its Singapore plasma fractionation facility.

The Board wishes to thank Mr Spee for his support over the last few years and wishes him well in his future endeavours.

****ENDS****

For more information please contact:

Contact:
Tom Rowe
Company Secretary
+61 2 8415 7300
tom.rowe@nusep.com

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global BioSeparations market. NuSep recently acquired BioInquire which developed the ProteolQ software enabling NuSep to offer a total Proteomics solution from ***Fraction to Function***. The company has offices in both Sydney Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:






Gels – NuSep manufactures and sells precast gels including the innovative nUView Gels, which can be visualised 2 minutes after use.

NuSep Holdings Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 8415 7300
Facsimile +61 2 8415 7399

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

-  **Separation Instruments** – NuSep has developed two unique biological separation instruments. The ProteomeSep was released in 2009 and can separate biological samples into 8 fractions for use in the proteomic market. The SpermSep separates sperm for fertility treatments such as IVF.
-  **Proteomics Software** – NuSep offers the unique ProteoIQ software for the analysis of complex mass spec samples. This software is also designed to identify bio markers.
-  **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

About PRIME Biologics Pte Ltd

PRIME Biologics is a Singapore based biotech company that has developed a disposable procedure for the processing of plasma proteins. PRIME Biologics is currently a wholly owned subsidiary of NuSep Holdings Limited (ASX: NSP). PRIME Biologics process is based on the **P**reparative **I**solation by **M**embrane **E**lectrophoresis (PRIME) technology developed by NuSep. PRIME provides disposable modular processing that is 'electronically' driven membrane fractionation.

The PRIME process increases product yields to over 90% relative to the existing process 50% while increasing product safety. Further, PRIME Biologics process can produce multiple plasma products in hours compared to days, which is required by the current manufacturers.

The initial application for the PRIME process will be the *Currently Unprocessable Plasma* which represents approximately 50% of all the plasma collected in many countries.